Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

NCT04957212 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Carboplatin
DRUG: Docetaxel

Sponsor

Cinnagen